Potent multikinase inhibitor that targets the RAF/MEK/ERK pathway in tumor cells, and tyrosine kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Inhibits Raf-1, B-Raf, VEGFR-2, VEGFR-3, PDGFR-β, Flt3, c-KIT and FGFR-1 (IC50 values are 6 nM, 22 nM, 90 nM, 20 nM, 57 nM, 58 nM, 68 nM and 580 nM in cell-free assays, respectively).
Shipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
Soluble in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Liu L et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res66:11851-8 (2006).
Read more (PubMed: 17178882) »
Adnane L et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol407:597-612 (2006).
Read more (PubMed: 16757355) »
Wilhelm SM et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res64:7099-109 (2004).
Read more (PubMed: 15466206) »